Fundamental Analysis of Supernus Pharma Inc. - Growth / Value Index
SUPN - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 12.50
Very Expensive - Price to Intrinsic Value of 38.39
Book Value in last 3 years is trending down
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -102.95 | 63041.48 | 213134 % | |
| Price to Book | 1.74 | 1752.82 | 86443.46 % | 1.74 |
| Price to Sales | 2.67 | 2645.63 | 98249.84 % | |
| Enterprise Value to EBITDA Multiple | 45.90 | 13321.86 | 95167.93 % |
SUPN - Profitability Highlights
Profitability Analysis
Piotroski F Score - Good Value of 7.0
Company Earning excess return
Tsr Profitability Index - Very Poor Score of 5.00
Very Low Dividend Yield of 0 %
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -1.69 | 2.78 | -59.41 % | 0.0133 |
| Return On Asset | -1.12 | 2.01 | -43.76 % | 0.0095 |
| Net Profit Margin | -2.60 | 4.20 | -53.88 % | 0.086 |
| Operating Profit Margin | 1.07 | 4.92 | -27.98 % | -2.20 |
| EBITDA Margin | 5.59 | 19.86 | -11.92 % | -2.20 |
Highlights
| Market Cap | 1599.75 M |
| Enterprise Value | 1533.03 M |
| Price/Book TTM | 1.74 |
| Outstanding Share | 54974.30 K |
| Float/ Outstanding Share | 87.21% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0.971 |
| Piotroski F Score | 7.00 |
| Altman Z Score | 3.99 |
| Sloan Ratio | -0.053 |
| Peter Lynch Fair Value | 0 |
SUPN - Growth Highlights
Growth Analysis
Tsr Growth Index - Poor Score of 22.71
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 597401 K | 8.50 % | 12.58 % |
| Gross Profit | 558173 K | 9.76 % | 0.721 % |
| EBITDA | 33401.00 K | 19.41 % | 113.80 % |
| Net Profit | -15508.00 K | 57.80 % | 89.45 % |
| EPS | -0.283 | 99.95 % | NA |
SUPN - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 93.75
Altman Z Score of 3.97 suggests good Stability
Paid More Than 50% of Debt, Heading towards debt free
Debt to equity ratio has decreased and is lowest in last five years
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0090 | -98.01 % | 0.0098 |
| Cash Ratio | 0.878 | 30.97 % | |
| Quick Ratio | 1.43 | 53.36 % | 1.49 |
| Shareholders Equity | 72.12 | 38.56 % | |
| Debt to EBITDA | 0.069 | -97.43 % |
Historical Valuation Ratios of Supernus Pharma Inc.
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Supernus Pharma Inc.
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Supernus Pharma Inc.
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Supernus Pharma Inc.
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)